Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences
August 27 2020 - 4:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused
biopharmaceutical company working to create best-in-class cancer
therapies, today announced that management will present at the
following upcoming virtual investor conferences:
- Citi 15th Annual BioPharma Virtual Conference, Wednesday,
September 9 at 1:30 pm ET
- 2020 Cantor Global Virtual Healthcare Conference, Wednesday,
September 16 at 4:40pm ET
- Morgan Stanley Virtual 18th Annual Global Healthcare
Conference, Friday, September 18 at 10:15 am ET
A live audio webcast of each presentation will be available by
visiting the “Investors” section of the Arcus website at
www.arcusbio.com. A replay of each webcast will be available for at
least two weeks following the live event.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical
company leveraging its deep cross-disciplinary expertise to
discover highly differentiated therapies and to develop a broad
portfolio of novel combinations addressing significant unmet needs.
Arcus currently has four molecules in clinical development:
AB928, the first and only dual A2a/A2b adenosine receptor
antagonist in the clinic, is being evaluated in multiple Phase 1b/2
studies across different indications, including prostate,
colorectal, non-small cell lung, pancreatic and triple-negative
breast cancers. AB680, the first small-molecule CD73
inhibitor in the clinic, is in Phase 1 development for first-line
treatment of metastatic pancreatic cancer in combination with
zimberelimab and gemcitabine/nab-paclitaxel. AB154, an
anti-TIGIT monoclonal antibody and new potential immuno-oncology
backbone therapy, is in a three-arm randomized Phase 2 study for
first-line treatment of PD-L1-high metastatic non-small cell lung
cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab
and AB154 plus AB928 with zimberelimab. Zimberelimab
(AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being
evaluated in a Phase 1b study as monotherapy for cancers with no
approved anti-PD-1 treatment options, and in various combinations
across the portfolio. For more information about Arcus Biosciences,
please visit www.arcusbio.com.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200827005635/en/
Katherine Bock (510) 694-6231 kbock@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcus Biosciences (NYSE:RCUS)
Historical Stock Chart
From Apr 2023 to Apr 2024